News & Articles
Discover our latest news features, insightful blog posts, and important updates from AuctuCel.
AuctuCel Establishes First Distribution Centre in China to Strengthen Regional Supply Chain
Singapore / China — January 2026 AuctuCel, a Singapore-based biotechnology company spun out of A*STAR’s Bioprocessing Technology Institute, has announced the establishment of its first distributioncentre in China , marking a key milestone in the company’s regional expansion. The new distribution centre strengthens AuctuCel’s ability to support customers across China and the wider Asia region , enabling shorter lead times , greater supply consistency , and improved regional responsiveness . This development reinforces the company’s commitment to building a reliable and scalable supply chain as demand for its products continues to grow.
AuctuCel Signs MOU with StellarCell Bio to Advance Exosome and Cell Culture Research
(From left) Mr. Zhou, Chief Strategy Officer of StellarCell Bio; Ms. Guo, General Manager of StellarCell Bio; together with Dr Fhu Chee Wai, Co-founder and Chief Executive Officer of AuctuCel, and Dr Zach Pang, Co-founder and Chief Scientific Advisor of AuctuCel, at the MOU signing ceremony to strengthen collaboration in cell culture and bioprocess optimisation. We’re pleased to share that AuctuCel has signed an MOU with StellarCell BioMedicine Inc. (星誠細胞生醫) , a Taiwan-based company focused on regenerative medicine and cell therapy. Under this collaboration, AuctuCel will provide our serum-free and xeno-free specialised media to support StellarCell Bio’s exosome and extracellular vesicle (EV) culture research. Research outcomes will be shared between both teams, with the potential for joint publications. Where needed, we will also support culture media optimisation to meet performance requirements.
Syarikat Spin-off A*STAR BTI, AuctuCel lancar platform AI
Mengurangkan kos pembangunan sehingga 80 peratus, mempercepatkan garis masa sebanyak 83 peratus serta meningkatkan produktiviti sel lebih 20 peratus. SINGAPURA, 12 September 2025 – AuctuCel, syarikat bioteknologi baharu hasil spin-off daripada A*STAR Bioprocessing Technology Institute (BTI) melancarkan platform proprietari dikenali sebagai Fluxperior iaitu satu sistem berkuasa kecerdasan buatan (AI) yang dibangunkan bagi mengurangkan kos dan masa dalam menghasilkan resipi nutrien untuk pertumbuhan sel yang digunakan dalam rawatan perubatan. Dibangunkan oleh penyelidik A*STAR BTI, Fluxperior menggabungkan pemodelan komputer dengan AI untuk meramal keperluan nutrien sel secara tepat, sekali gus menggantikan kaedah tradisional berasaskan proses cuba jaya yang kebiasaannya mengambil masa lebih enam bulan. Hasil kajian menunjukkan Fluxperior mampu mengurangkan kos pembangunan sehingga 80 peratus, mempercepatkan garis masa sebanyak 83 peratus serta meningkatkan produktiviti sel lebih 20 peratus.
Singapore's A*STAR BTI spinoff AuctuCel launches AI platform to slash cell medicine production costs by 80%
Image Caption: left to right: Lingesh Kumar, Scientific and Operations Manager of AuctuCel, Dr Fhu Chee Wai, Co-founder & CEO of AuctuCel, Prof Andy Hor, Deputy Chief Executive (Research), A*STAR, and A/Prof Andre Choo, Deputy Executive Director, Bioprocessing Technology Institute, A*STAR, Dr Zach Pang, Co-founder & Chief Scientific Officer of AuctuCel Enterprise Singapore's Startup SG program has awarded AuctuCel $65,000 to develop an innovative product built on BTI's expertise in culture media development, bioprocess analytics, and computational modeling. AuctuCel, a biotech spin-off from Singapore's A*STAR Bioprocessing Technology Institute (BTI), has officially launched with its proprietary Fluxperior platform — an artificial intelligence-powered system designed to dramatically reduce the cost and time required to develop nutrient “recipes” for growing cells used in medical treatments. Developed by A*STAR BTI researchers, Fluxperior combines computer modelling with AI to predict exactly what nutrients cells need to thrive, replacing the traditional trial-and-error process that typically takes more than six months. Proven results show Fluxperior can cut development costs by up to 80%, speed up timelines by 83%, and boost cell productivity by more than 20%.
AuctuCel Celebrates First Anniversary with Official Launch and Strategic Milestones
Image Caption: left to right: Lingesh Kumar, Scientific and Operations Manager of AuctuCel, Dr Fhu Chee Wai, Co-founder & CEO of AuctuCel, Prof Andy Hor, Deputy Chief Executive (Research), A*STAR, and A/Prof Andre Choo, Deputy Executive Director, Bioprocessing Technology Institute, A*STAR, Dr Zach Pang, Co-founder & Chief Scientific Officer of AuctuCel AuctuCel, a pioneering biotech spin-off from Singapore’s A*STAR Bioprocessing Technology Institute, marked its first anniversary with a launch event on 9 September 2025, bringing together industry leaders, scientists, investors, and partners from across the region. In just one year since incorporation, AuctuCel has achieved significant milestones that underscore its vision of transforming biomanufacturing with precision and innovation. The event was graced by Prof Andy Hor, Deputy Chief Executive (Research), A STAR, and A/Prof Andre Choo, Deputy Executive Director, Bioprocessing Technology Institute, A STAR, who shared their presence and speeches.
AuctuCel has signed an MoU with Shimadzu (Asia Pacific) to advance cell culture media optimisation and drive innovation in biomanufacturing
Featuring from left to right: Sandhya Nargund | Prem Anand | Chee Wai Fhu | Boon Tong Koh We’re beyond excited to share this big milestone 🎉 — AuctuCel has signed an MoU with Shimadzu (Asia Pacific) to advance cell culture media optimisation and drive innovation in biomanufacturing. It’s an honour to collaborate with a global science leader like Shimadzu, made even more meaningful as it coincides with Shimadzu Corporation’s 150th anniversary — a remarkable legacy of scientific excellence. At AuctuCel , we use computational modelling and AI-powered design to create next-generation culture media that make development faster, smarter, and easier to scale. By integrating our digital media design platform with Shimadzu’s advanced analytical technologies and modelling capabilities, we’re unlocking deeper insights, improving precision, and paving the way for smarter, faster media innovation.
